ERI1 exoribonuclease family member 3Genealiases: PINT1 · PRNPIP
Q-omics provides the consensus-scored ERI3 profile across patient tissues and cancer cell-line models. ERI3 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, ERI3 is differentially expressed in 15, with the highest sampling consensus in KICH. Additionally, ERI3 protein abundance shows 20,997 significant protein co-abundance associations, with the highest sampling consensus in LUAD. Together, these results highlight ACC, KICH, and LUAD as cancer lineages where ERI3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ERI3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ERI3 survival associations across molecular data types. ERI3 RNA expression shows survival associations in the most cancer types (20), followed by mutation status (5) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ERI3 RNA expression–survival associations across cancer types. High ERI3 expression shows unfavorable associations in ACC, BLCA, KICH, LIHC, MESO and LGG. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for ERI3 RNA expression.
This table summarizes ERI3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 6. The strongest signals are observed in HNSC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for ERI3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ERI3 shows lower tumor expression in KICH and THCA and higher tumor expression in COAD, HNSC, LIHC and LUSC. The KICH box plot shows higher ERI3 RNA expression in normal versus tumor tissue (log2 FC = −1.567, t-test p < 0.001).
This table shows molecular features associated with ERI3 in patient tissues and cancer cell lines. In patient samples, ERI3 shows the broadest associations at the RNA and protein expression levels, with LUAD recurring as the lineage with the largest associated feature set. In cancer cell lines, ERI3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in KIDNEY and LARGE_INTESTINE.
